DK3518897T3 - Depotformulering af optalmisk lægemiddel og anvendelser deraf - Google Patents

Depotformulering af optalmisk lægemiddel og anvendelser deraf Download PDF

Info

Publication number
DK3518897T3
DK3518897T3 DK17857601.3T DK17857601T DK3518897T3 DK 3518897 T3 DK3518897 T3 DK 3518897T3 DK 17857601 T DK17857601 T DK 17857601T DK 3518897 T3 DK3518897 T3 DK 3518897T3
Authority
DK
Denmark
Prior art keywords
formal
deposit
medicinal product
optional medicinal
optional
Prior art date
Application number
DK17857601.3T
Other languages
English (en)
Inventor
Deepank Utkhede
Catherine Jones
David Wiseman
Original Assignee
Mati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mati Therapeutics Inc filed Critical Mati Therapeutics Inc
Application granted granted Critical
Publication of DK3518897T3 publication Critical patent/DK3518897T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00772—Apparatus for restoration of tear ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
DK17857601.3T 2016-09-30 2017-09-30 Depotformulering af optalmisk lægemiddel og anvendelser deraf DK3518897T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662402938P 2016-09-30 2016-09-30
PCT/US2017/054654 WO2018064648A1 (en) 2016-09-30 2017-09-30 Ophthalmic drug sustained release formulation and uses thereof

Publications (1)

Publication Number Publication Date
DK3518897T3 true DK3518897T3 (da) 2022-03-07

Family

ID=61763607

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17857601.3T DK3518897T3 (da) 2016-09-30 2017-09-30 Depotformulering af optalmisk lægemiddel og anvendelser deraf

Country Status (10)

Country Link
US (2) US11324693B2 (da)
EP (2) EP4046609A1 (da)
JP (3) JP7088918B2 (da)
KR (1) KR20190061047A (da)
CN (1) CN110475543B (da)
CA (1) CA3038115A1 (da)
DK (1) DK3518897T3 (da)
ES (1) ES2907847T3 (da)
IL (1) IL265677A (da)
WO (1) WO2018064648A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3038115A1 (en) * 2016-09-30 2018-04-05 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
EP3990042A4 (en) 2019-06-27 2023-07-19 Layerbio, Inc. METHODS AND SYSTEMS FOR RELEASING EYE DEVICES

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
US5273530A (en) 1990-11-14 1993-12-28 The University Of Rochester Intraretinal delivery and withdrawal instruments
JP4194114B2 (ja) * 1994-02-23 2008-12-10 ビーエム リサーチ エイ／エス 制御放出組成物
US5632773A (en) * 1994-05-03 1997-05-27 Allergan, Inc. Biostable corneal implants
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
AUPP279698A0 (en) * 1998-04-03 1998-04-30 Sunscape Developments Limited Sustained release formulation
WO2001049352A2 (en) 2000-01-03 2001-07-12 Johns Hopkins University Device and method for manual retinal vein catheterization
US6954933B2 (en) 2000-10-30 2005-10-11 Microsoft Corporation Method and apparatus for providing and integrating high-performance message queues in a user interface environment
DE60318446T2 (de) * 2002-07-15 2008-05-21 Alcon Inc. Nichtpolymere lipophile pharmazeutische implantat-zusammensetzungen für die intraokulare anwendung
JP2006520217A (ja) 2003-02-26 2006-09-07 メディバス エルエルシー 生物活性ステントおよびその使用方法
US7662864B2 (en) 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
US20050129731A1 (en) 2003-11-03 2005-06-16 Roland Horres Biocompatible, biostable coating of medical surfaces
CN1910691A (zh) 2004-01-19 2007-02-07 皇家飞利浦电子股份有限公司 具有定中心装置的盘盒
US8529927B2 (en) 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
AU2005269988B2 (en) 2004-07-02 2012-02-02 Mati Therapeutics Inc. Treatment medium delivery device and methods for delivery
EP1773350B1 (en) 2004-07-12 2013-05-29 Allergan, Inc. Opthalmic compositions for treating ophthalmic conditions
WO2006028361A1 (es) * 2004-09-09 2006-03-16 Arturo Jimenez Bayardo Implantes y microesferas de liberación prolongada de fármacos de uso oftálmico y metodos para prepararlos
US20080038317A1 (en) * 2004-09-10 2008-02-14 Chin-Ming Chang Therapeutic Lacrimal Canalicular Inserts And Related Methods
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
WO2006106368A1 (en) 2005-04-04 2006-10-12 Kyosho Corporation Multi-cylinder two-stroke radial engine
NZ572193A (en) 2006-03-31 2011-10-28 Quadra Logic Tech Inc Nasolacrimal drainage system implants for drug therapy with non-fluid swellable retention structure around drug core
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
KR20140032505A (ko) * 2006-11-09 2014-03-14 알콘 리서치, 리미티드 약물 전달용 수불용성 폴리머 매트릭스
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
JP4309438B2 (ja) 2007-03-20 2009-08-05 株式会社東芝 情報記録再生装置
US7839044B2 (en) 2007-03-23 2010-11-23 Panasonic Corporation Rotor magnet, spindle motor comprising the same, recording and reproducing apparatus, and jig for manufacturing the same
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20090196905A1 (en) * 2008-02-06 2009-08-06 Spada Lon T Stabilization of mitochondrial membranes in ocular diseases and conditions
KR20100135748A (ko) * 2008-02-21 2010-12-27 센주 세이야꾸 가부시키가이샤 아쥬반트로서의 안과용 ｎｓａｉｄ
AU2010206610A1 (en) * 2009-01-23 2011-08-11 Qlt Inc. Sustained released delivery of one or more agents
EP2503969A1 (en) 2009-11-27 2012-10-03 QLT Inc. Lacrimal implants including split and insertable drug core
KR102126007B1 (ko) 2010-01-22 2020-06-24 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
EP4122384A1 (en) 2011-06-16 2023-01-25 Abbott Diabetes Care, Inc. Temperature-compensated analyte monitoring devices, systems, and methods thereof
ES2540151B1 (es) * 2013-10-11 2016-02-29 Farmalider S.A. Composición farmacéutica de ibuprofeno y tramadol para uso oftálmico
RU2629449C2 (ru) 2014-05-07 2017-08-29 Общество С Ограниченной Ответственностью "Яндекс" Устройство, а также способ выбора и размещения целевых сообщений на странице результатов поиска
EP3188688B1 (en) * 2014-09-06 2021-11-03 Integral Biosystems LLC Methods and biocompatible compositions to achieve sustained drug release in the eye
US10603274B2 (en) * 2016-09-30 2020-03-31 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
CA3038115A1 (en) * 2016-09-30 2018-04-05 Mati Therapeutics Inc. Ophthalmic drug sustained release formulation and uses thereof
US10880072B2 (en) 2018-06-20 2020-12-29 Verizon Patent And Licensing Inc. Systems and methods for controlled random endorsement in a blockchain network
US11695537B2 (en) 2021-06-01 2023-07-04 Bose Corporation Digital signal processor/network synchronization

Also Published As

Publication number Publication date
CN110475543B (zh) 2023-07-25
JP7324342B2 (ja) 2023-08-09
KR20190061047A (ko) 2019-06-04
EP3518897A4 (en) 2020-05-27
CA3038115A1 (en) 2018-04-05
JP7088918B2 (ja) 2022-06-21
US11957784B2 (en) 2024-04-16
JP2022125050A (ja) 2022-08-26
US20230091568A1 (en) 2023-03-23
IL265677A (en) 2019-05-30
US20200222317A1 (en) 2020-07-16
EP3518897A1 (en) 2019-08-07
JP2019534872A (ja) 2019-12-05
WO2018064648A1 (en) 2018-04-05
US11324693B2 (en) 2022-05-10
ES2907847T3 (es) 2022-04-26
EP4046609A1 (en) 2022-08-24
JP2023133438A (ja) 2023-09-22
EP3518897B1 (en) 2022-02-09
CN110475543A (zh) 2019-11-19

Similar Documents

Publication Publication Date Title
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3411398T3 (da) Målrettede terapeutiske midler og anvendelse heraf
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3504242T3 (da) Anti-ox40-antistoffer og anvendelse deraf
DK3283106T3 (da) Terapeutiske antistoffer og anvendelser deraf
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3303395T3 (da) Anti-cd40-antistoffer og anvendelser deraf
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
DK3210977T3 (da) Hidtil ukendt aminoalkylbenzothiazepinderivat og anvendelse deraf
DK3380101T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3265448T3 (da) Riluzol-prodrugs og anvendelse deraf
DK3149042T3 (da) PD-L1-antistoffer og anvendelser deraf
DK3155024T3 (da) Opholdsstrukturer og relaterede fremgangsmåder
DK3099717T3 (da) Antistofmolekyler med tim-3 og anvendelser deraf
DK3218358T3 (da) Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3487505T3 (da) Indgivelse og dosering af diaminophenothiaziner
DK3345587T3 (da) Beholderholdeelement og medicinsk beholdersæt
DK3514153T3 (da) Pyrimidinforbindelse og farmaceutisk anvendelse deraf
DK3236991T3 (da) Fgf21-derivater og anvendelser deraf
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3110447T3 (da) Anti-EGFR-antistof og anvendelser heraf